Proposed Directors of Tirupati Graphite explain why they have requisitioned an GM. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMTFB.L Share News (MTFB)

  • There is currently no data for MTFB

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Cash Shell Motif Bio Swings To Interim Loss On Derivative Liabilities

Mon, 12th Oct 2020 11:50

(Alliance News) - Motif Bio PLC on Monday said it swung to a loss in the first half of 2020 as it searches for a reverse takeover candidate.

The AIM-listed cash shell posted a loss for the half year ended June 30 of USD987,000 versus USD4.8 million profit a year prior.

The first half loss was primarily attributed to revaluation of derivative liabilities, which amounted to a loss of USD305,000 versus a gain of USD5.6 million.

The company said it is maintaining its focus on sourcing and completing an appropriate reverse takeover candidate in an effort to deliver value to shareholders.

This follows the company's re-organisation following shareholder approval at the end of 2019.

This has allowed Motif Bio to be unhindered by its previous obligations to its former operating subsidiary, Motif Biosciences Inc. This has given the the company the flexibility to pursue a reverse takeover candidate for the company.

Going forward, Motif Bio said it may require additional capital though the issuing of securities would mean "existing stockholders may experience significant dilution."

The company had USD800,000 cash at June 30.

By Greg Roxburgh; gregroxburgh@alliancenews.com

Copyright 2020 Alliance News Limited. All Rights Reserved.

More News
1 Jun 2020 11:16

UK TRADING UPDATE SUMMARY: Fuller Smith & Turner Gets GBP100 Million

UK TRADING UPDATE SUMMARY: Fuller Smith & Turner Gets GBP100 Million

Read more
5 May 2020 10:58

Motif Bio Raises GBP650,000 To Strengthen Cash Position

Motif Bio Raises GBP650,000 To Strengthen Cash Position

Read more
5 May 2020 09:17

Motif Bio raises ?0.65m as it hunts for reverse takeover opportunity

(Sharecast News) - Motif Bio, which has been reclassified as an AIM rule 15 cash shell, has raised a total of ?0.65m before expenses via a placing, it announced on Tuesday, through the issue of 162,500,000 ordinary shares with an institutional investor at a price of 0.4p each.

Read more
4 May 2020 15:42

UK EXECUTIVE CHANGE SUMMARY: Scapa Healthcare, Industrial Heads Resign

UK EXECUTIVE CHANGE SUMMARY: Scapa Healthcare, Industrial Heads Resign

Read more
14 Apr 2020 17:12

Motif Bio Notes Hike In Share Price, Still Waiting For Sale Of Assets

Motif Bio Notes Hike In Share Price, Still Waiting For Sale Of Assets

Read more
19 Mar 2020 14:51

Motif Bio Still Seeks To Make Acquisition As Working Capital Dwindles

Motif Bio Still Seeks To Make Acquisition As Working Capital Dwindles

Read more
18 Mar 2020 15:33

Motif Bio struggling to find reverse takeover opportunity

(Sharecast News) - Motif Bio updated the market on its corporate developments on Wednesday, having been reclassified as an AIM rule 15 cash shell.

Read more
28 Jan 2020 11:31

Motif Bio And Hercules Amend Agreement To Facilitate Iclaprim Sale

Motif Bio And Hercules Amend Agreement To Facilitate Iclaprim Sale

Read more
26 Nov 2019 18:15

Motif Bio To De-List From Nasdaq, Last Day Of Trading December 16

Motif Bio To De-List From Nasdaq, Last Day Of Trading December 16

Read more
18 Nov 2019 13:50

Five Motif Bio Non-Executive Directors Leave As Part Of Restructuring

Five Motif Bio Non-Executive Directors Leave As Part Of Restructuring

Read more
11 Nov 2019 09:52

Motif Bio Seals Clinical Research Firm Settlement Without Payments

Motif Bio Seals Clinical Research Firm Settlement Without Payments

Read more
11 Nov 2019 09:40

Motif Bio reaches settlement with former clinical research organisation

(Sharecast News) - Motif Bio announced on Monday that its subsidiary Motif BioSciences has reached an agreement with its former clinical research organisation to settle all obligations without further payment.

Read more
25 Oct 2019 17:34

Invesco Cuts Stake In Biopharmaceutifcal Firm Motif Bio To 8.4%

Invesco Cuts Stake In Biopharmaceutifcal Firm Motif Bio To 8.4%

Read more
24 Oct 2019 16:05

Motif Bio announces US Army-funded evaluation of 'iclaprim'

(Sharecast News) - Clinical-stage biopharmaceutical company Motif Bio has signed an agreement with the Walter Reed Army Institute of Research (WRAIR) to conduct pre-clinical testing to evaluate novel combinations with 'iclaprim', to improve safety and efficacy administered by a novel enhanced aerosol technology, it announced on Thursday.

Read more
24 Oct 2019 12:01

Motif Bio Teams Up With US Forces To Look Into Iclaprim Use

Motif Bio Teams Up With US Forces To Look Into Iclaprim Use

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.